Literature DB >> 26205840

European Code against Cancer 4th Edition: Obesity, body fatness and cancer.

Annie S Anderson1, Timothy J Key2, Teresa Norat3, Chiara Scoccianti4, Michele Cecchini5, Franco Berrino6, Marie-Christine Boutron-Ruault7, Carolina Espina4, Michael Leitzmann8, Hilary Powers9, Martin Wiseman10, Isabelle Romieu11.   

Abstract

It is estimated that over half the population of the European Union (EU) is overweight or obese due to an imbalance between energy expenditure and energy intake; this is related to an obesogenic environment of sociocultural, economic and marketing challenges to the control of body weight. Excess body fat is associated with nine cancer sites - oesophagus, colorectum, gall bladder, pancreas, postmenopausal breast, endometrium, ovary, kidney and prostate (advanced) - and 4-38% of these cancers (depending on site and gender) can be attributed to overweight/obesity status. Metabolic alterations which accompany excess body weight are accompanied by increased levels of inflammation, insulin, oestrogens and other hormonal factors. There are some indications that intentional weight loss is associated with reduced cancer incidence (notably in postmenopausal breast and endometrial cancers). Excess body weight is also a risk factor for several other diseases, including diabetes and heart disease, and is related to higher risk of premature death. In reviewing the current evidence related to excess body fat and cancer, the European Code against Cancer Nutrition Working Group has developed the following recommendation: 'Take action to be a healthy body weight'.
Copyright © 2015 International Agency for Research on Cancer. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BMI; Body fat; Cancer; Central obesity; Europe; Obesity; Primary prevention; Weight

Mesh:

Year:  2015        PMID: 26205840     DOI: 10.1016/j.canep.2015.01.017

Source DB:  PubMed          Journal:  Cancer Epidemiol        ISSN: 1877-7821            Impact factor:   2.984


  41 in total

1.  The Association Between Salivary Ghrelin Levels with Anthropometric Measures in Underweight, Normal, Overweight and Obese Healthy Adult Males.

Authors:  Mona Mohamed Ibrahim Abdalla; Soon Siew Choo
Journal:  Eur Endocrinol       Date:  2020-02-28

2.  An anti-inflammatory dietary intervention to reduce breast cancer recurrence risk: Study design and baseline data.

Authors:  Amelie G Ramirez; Dorothy Long Parma; Edgar Muñoz; Kristin D Mendoza; Crystel Harb; Alan E C Holden; Michael Wargovich
Journal:  Contemp Clin Trials       Date:  2017-03-22       Impact factor: 2.226

Review 3.  The Influence of Sedentary Behavior on Cancer Risk: Epidemiologic Evidence and Potential Molecular Mechanisms.

Authors:  Carmen Jochem; Birgit Wallmann-Sperlich; Michael F Leitzmann
Journal:  Curr Nutr Rep       Date:  2019-09

4.  Cancers Due to Excess Weight, Low Physical Activity, and Unhealthy Diet.

Authors:  Gundula Behrens; Thomas Gredner; Christian Stock; Michael F Leitzmann; Hermann Brenner; Ute Mons
Journal:  Dtsch Arztebl Int       Date:  2018-09-03       Impact factor: 5.594

Review 5.  Weight Loss Randomized Intervention Trials in Female Cancer Survivors.

Authors:  Rowan T Chlebowski; Marina M Reeves
Journal:  J Clin Oncol       Date:  2016-11-07       Impact factor: 44.544

6.  Is there a Reason Why Obese Patients Choose Either Conservative Treatment or Surgery?

Authors:  Lars Fischer; Anna-Laura Wekerle; Johannes Sander; Felix Nickel; Adrian T Billeter; Ulrike Zech; Thomas Bruckner; Beat P Müller-Stich
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

Review 7.  Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state.

Authors:  Zora Djuric
Journal:  Transl Res       Date:  2016-07-28       Impact factor: 7.012

8.  Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer.

Authors:  Rong-Liang Shi; Ning Qu; Tian Liao; Wen-Jun Wei; Zhong-Wu Lu; Ben Ma; Yu-Long Wang; Qing-Hai Ji
Journal:  Tumour Biol       Date:  2016-01-05

9.  Protopanaxadiol and metformin synergistically inhibit estrogen-mediated proliferation and anti-autophagy effects in endometrial cancer cells.

Authors:  Chun-Jie Gu; Jiao Cheng; Bing Zhang; Shao-Liang Yang; Feng Xie; Jian-Song Sun; Li-Qing Huang; Jin-Jin Yu; Ming-Qing Li
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

10.  Development and Validation of Lifestyle-Based Models to Predict Incidence of the Most Common Potentially Preventable Cancers.

Authors:  Juliet A Usher-Smith; Stephen J Sharp; Robert Luben; Simon J Griffin
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-09-13       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.